Home
My Account
About Us
Forum
Contact us
الواجهة العربية
epharmaweb.com
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz
Newsletter

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



Promising Drug for Multiple Sclerosis


Promising Drug for Multiple Sclerosis

(ePharmaNews) - Diagnosing multiple sclerosis carries a disastrous impact when told to young men and women. Blindness, disability and various neurological deficits may develop, and, to make things worse, no reliable treatment is available. Anyway, a recent study may give hope as it found a promising drug to control MS.

According to the results of a phase two clinical trial to be presented as Emerging Science (formerly known as Late-Breaking Science) at the American Academy of Neurology’s 64th Annual Meeting in New Orleans April 21 to April 28, 2012, an investigational oral drug called ONO-4641 reduced the number of lesions  in people with multiple sclerosis (MS).
   
For the study, 407 people between the ages of 18 and 55 with relapsing-remitting MS were randomly given placebo, 0.05 mg, 0.10 mg, or 0.15 mg of ONO-4641 once per day for 26 weeks. People were included in the study if they  had two or more relapses in the two years prior to the study, one or more relapses within the year prior to the study or one or more new MS-related brain lesions, also known as Gd-enhancing lesions, detected on MRI within three months prior to the study. Brain scans were performed every four weeks from 10 to 26 weeks.

Brain lesions is the main cause of MS symptoms such as vision disorders and mobility problems, it is caused by the immune system's attack to the myelin sheath surrounding fibers in the brain and spinal cord, which manifests by a variety of symptoms.

At the end of the study, people taking 0.05, 0.10, or 0.15 mg of ONO-4641 had 82 percent, 92 percent and 77 percent fewer Gd-enhancing brain lesions, respectively, compared to placebo.

“In light of recent issues in the oral MS drug market, this is welcome news,” said study author Timothy Vollmer, MD, of the University of Colorado in Denver and a Fellow with the American Academy of Neurology.


Adverse events appeared to be dose related and included cardiovascular events, such as a slower heartbeat, blood pressure changes, and an AV block, which is the impairment of the conduction between the atria and ventricles of the heart. Other adverse events included liver enzyme elevations. In addition, grade four lymphopenia, which is an abnormally low level of lymphocytes in the blood, occurred in four percent of people receiving the 0.15 mg dose of ONO-4641 and in one percent of those receiving the 0.10 mg dose.



Prepared by: Laila Nour
Translated by: Marcell Shehwaro


Source :

ePharmaNews






Other Comments

Add a comment

You must sign in to use this servcie

Username:
Password:


facebook comments

Forgot your password


sign up

Consultants Corner

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Dr. Talal Sabouni

Dr. Talal Sabouni UROLOGY AND KIDNEY TRANSPLANT

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist
Poll

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details